157. Sturge-Weber syndrome Clinical trials / Disease details
Clinical trials : 10 / Drugs : 13 - (DrugBank : 4) / Drug target genes : 5 - Drug target pathways : 63
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02080624 (ClinicalTrials.gov) | January 2011 | 18/4/2013 | Efficacy and Safety Study of Topical Rapamycin Associated With Pulsed Dye Laser in Patients With Sturge-Weber Syndrome | Phase II, Randomized, Triple Blind, Intra-individually Placebo-controlled Clinical Trial to Assess the Efficacy and Safety of Topical Rapamycin Associated With Pulsed Dye Laser in Patients With Sturge-Weber Syndrome. | Sturge- Weber Syndrome | Drug: Drug: Topical Rapamycin | Clinica Universidad de Navarra, Universidad de Navarra | NULL | Completed | 16 Years | 65 Years | Both | 23 | Phase 2 | Spain |